The Interorganizational Task Force on Biovigilance first met in 2006 to explore the possibility of creating a comprehensive biovigilance network in the U.S. The task force — composed of key stakeholders in the transfusion and cellular therapies communities, including blood centers, hospitals, and the federal government — has worked to achieve this goal through its steering committee and working groups.
To begin development of the U.S. Biovigilance Network, AABB built on its past collaborations with governmental and private sector partners in the transfusion and transplantation communities. This allowed the organization to secure participation and funding from hospitals, blood centers and companies as well as long-term commitments from the federal government. The association also was able to tap into its experience in data collection and analysis, including existing surveillance efforts for West Nile virus and Chagas’ disease.
With input from task force work groups, the first component of the network — a hemovigilance system to monitor adverse events associated with transfusions — was launched in February 2010. The Hemovigilance Module is part of the Centers for Disease Control and Prevention’s National Healthcare Safety Network — a secure, voluntary, Internet-based surveillance system that monitors patient and health care personnel safety.
Another network component, the Donor Hemovigilance System, was launched in October 2010 to track and reduce the occurrence of adverse events associated with blood donation.
Through its work groups, the task force continues to support development of enhancements to the hemovigilance software systems and contribute to the development of biovigilance systems for tissues and cell therapies. Expert groups are involved in the review and analysis of data and the development of interventions designed to improve patient care and donor health.